CJC-1295 DAC

CJC-1295 DAC

$140.00

Tetra-Substituted GHRH(1–29) Analog · Maleimidopropionyl Bioconjugate

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 29-amino-acid peptide derivative corresponding to the active core of human Growth Hormone-Releasing Hormone (GHRH₁–₂₉). Modified with four strategic amino acid substitutions (Ala²→D-Ala², Asn⁸→Gln⁸, Gly¹⁵→Ala¹⁵, and Gln²⁷→Leu²⁷), it features a C-terminal Lys(maleimidopropionyl) linker. This reactive bioconjugate tag covalently binds to circulating serum albumin upon administration, shielding the peptide from enzymatic degradation by Dipeptidyl Peptidase IV (DPP-IV) and renal filtration. Peer-reviewed studies (Teichman et al., 2006, JCEM; Ionescu et al., 2006) document its extended terminal half-life of 6–8 days and continuous activation of anterior pituitary somatotroph GHRH receptors, driving sustained, pulsatile surges of Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) elevation.

Supplied at 5mg.

SKU: CJC-DAC-5MG Categories: ,

Description

Overview

CJC-1295 with DAC (Drug Affinity Complex) is an engineered, 29-amino-acid synthetic analog of human Growth Hormone-Releasing Hormone (GHRH₁–₂₉). Incorporating four protective amino acid substitutions and a C-terminal maleimidopropionyl linker, the molecule covalently binds to circulating serum albumin in vivo.

This albumin bioconjugation shields the peptide core from Dipeptidyl Peptidase IV (DPP-IV) proteolysis and rapid renal clearance, extending its active half-life to 6–8 days. In laboratory models, CJC-1295 with DAC offers long-lasting stimulation of pituitary GHRH receptors, elevating baseline levels of Growth Hormone (GH) and IGF-1 while preserving natural secretory pulsatility.

Key Technical Specifications

Sequence YADAIFTQSYRKVLAQLSARKLLQDIMSR-Lys(maleimidopropionyl)-NH2
Molecular Formula C₁₆₅H₂₆₉N₄₇O₄₆
Molecular Weight ~3647.94 g/mol
CAS Number 863288-34-0
Elimination Half-Life ~6–8 days (in vivo, human albumin-bound)
Solubility Bacteriostatic Water / Sterile Water
Primary Class Long-Acting GHRH Receptor Agonist (Bioconjugate)

Biochemical Architecture & Mechanisms

1. Enzymatic Protection & Sequence Substitution

Native GHRH is rapidly inactivated by circulating enzymes. CJC-1295 incorporates specific residue modifications to preserve chemical structure:

  • D-Ala² Substitution: Direct resistance to primary DPP-IV catalytic cleavage.
  • Gln⁸, Ala¹⁵, Leu²⁷ Modifications: Enhanced structural stability and optimized GHRH receptor binding affinity.

2. Drug Affinity Complex (DAC) Chemistry

The C-terminal maleimidopropionyl linker binds specifically and covalently to the free thiol on Cysteine-34 (Cys³⁴) of endogenous serum albumin. This creates a circulating depot that effectively bypasses early endopeptidase degradation and rapid glomerular filtration.

3. Pituitary & Somatotrophic Axis Activation

  • GHRHR Agonism: Stimulates pituitary somatotrophs to elevate cAMP cascades and drive endogenous GH release.
  • Extended IGF-1 Secretion: Sustained plasma residence yields prolonged elevations of downstream hepatic IGF-1 output while preserving physiological pulse mechanics.

Pharmacokinetic Literature: Clinical studies (Teichman et al., 2006; Ionescu et al., 2006) confirmed that a single administration of CJC-1295 with DAC produces multi-fold, dose-dependent increases in mean plasma GH and IGF-1 levels spanning 10–14 days.

For laboratory research, educational, and analytical reference only. Strictly not for human or veterinary use.

Related products